Treatments, medicines, and vaccines have all been developed and tested in the healthcare industry. Major investment circles have taken notice of Cardinal Health, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., and CVS Health Corporation. The COVID-19 pandemic, according to Fidelity’s healthcare industry outlook research for 2021, has actually offered up new prospects in healthcare. The Russell 3000 Healthcare Index was up 19.3 percent in 2020, compared to only 20.9 percent for the general market index.
Insider Monkey looks at the 10 healthcare dividend stocks that hedge funds are buying. Hedge funds are purchasing Becton, Dickinson and Company, which is ranked 10th on our list of healthcare dividend stocks. The company’s revenue was $4.89 billion, up 26.85% year over year and $0.30 higher than analysts’ expectations. Hedge funds are buying Abbott Laboratories, which is ranked 9th on the list of healthcare dividend stocks. Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices are the company’s segments. Hedge funds are purchasing Medtronic Plc, which is ranked eighth on the list of healthcare dividend stocks. Implantable cardiac pacemakers and other medical devices are among the company’s device-based medical therapies. It has increased by 9.67% in the last six months and by 11.70% year to date. Pfizer Inc. is ranked 7th on the list of hedge funds’ favorite healthcare dividend stocks. Through its vaccination manufacture and delivery, the business is leading the fight against the coronavirus pandemic. Pfizer is a healthcare and biopharmaceutical corporation. Hedge funds are purchasing Gilead Sciences, Inc., which is ranked 6th on the list of healthcare dividend stocks. Revenue was $6.22 billion, up 20.88 percent year over year and $133 million higher than expected. For more details, click 10 Healthcare Dividend Stocks That Hedge Funds Are Buying.
